{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:55:29Z","timestamp":1786121729908,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032559","name":"Breakthrough T1D","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:22:11Z","timestamp":1779481331000},"page":"477-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Evidence for Cardiorenal Protection with Sodium\u2013Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes"],"prefix":"10.1016","volume":"55","author":[{"given":"Stuti","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ecl.2026.04.007_bib1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra2311526","article-title":"Prevention of cardiovascular disease in type 1 diabetes","volume":"390","author":"Manrique-Acevedo","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.007_bib2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/dc15-2399","article-title":"Mortality in type 1 diabetes in the DCCT\/EDIC versus the general population","volume":"39","author":"Lachin","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/dc20-3104","article-title":"Associations of microvascular complications with the risk of cardiovascular disease in type 1 diabetes","volume":"44","author":"Gubitosi-Klug","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.007_bib5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc26-S001","article-title":"1. Improving care and promoting health in populations: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.ecl.2026.04.007_bib6","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071945","article-title":"The effect of additional treatment with empagliflozin or semaglutide on endothelial function and arterial stiffness in subjects with type 1 diabetes Mellitus-ENDIS study","volume":"15","author":"Navodnik","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.007_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/life15050802","article-title":"Empagliflozin leads to faster improvement in arterial stiffness compared to dapagliflozin: a double-blind clinical","volume":"15","author":"Gonz\u00e1lez Campos","year":"2025","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70111","article-title":"Effect of glucagon-like Peptide-1 receptor agonists on cardiometabolic risk factors in type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"42","author":"Chen","year":"2026","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.007_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500173","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah","year":"2025","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.007_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/19322968231223991","article-title":"Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study","volume":"19","author":"Akturk","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.007_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/dia.2023.0490","article-title":"Efficacy of semaglutide in overweight and Obese patients with type 1 diabetes","volume":"26","author":"Garg","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"21","key":"10.1016\/j.ecl.2026.04.007_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216532","article-title":"Effectiveness and safety of GLP-1 receptor agonists in patients with type 1 diabetes","volume":"13","author":"Almohareb","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2337\/dc25-2379","article-title":"Tirzepatide in adults with type 1 diabetes: a phase 2 randomized placebo-controlled clinical trial","volume":"49","author":"Snaith","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.007_bib15","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.2337\/dc26-S008","article-title":"8. obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.007_bib16","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"Committee for Diabetes\u2217. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.007_bib17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2026.04.007_bib18","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2337\/dc26-S011","article-title":"11. chronic kidney disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.007_bib19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/clinem\/dgac618","article-title":"Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study","volume":"108","author":"Edwards","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10S","key":"10.1016\/j.ecl.2026.04.007_bib20","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2025m7ss8e68","article-title":"Cardiovascular risk prediction modelling with semaglutide in patients with type 1 diabetes","volume":"36","author":"Nardone","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ecl.2026.04.007_bib21","article-title":"Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?","volume":"15","author":"Resnick","year":"2024","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.007_bib22","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.007_bib23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2337\/dci23-0065","article-title":"Expanding the use of SGLT2i in diabetes beyond type 2","volume":"47","author":"Giaccari","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147391","article-title":"The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic \u03b2-Cell mass and glucose homeostasis in type 1 diabetes","volume":"11","author":"Cheng","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.007_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263285","article-title":"SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes","volume":"17","author":"Hodrea","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0797-6","article-title":"Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus","volume":"17","author":"Lunder","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00592-021-01686-x","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: meta-analysis of randomized controlled trials","volume":"58","author":"Rao","year":"2021","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pcd.2023.10.010","article-title":"Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"18","author":"Nan","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.ecl.2026.04.007_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112284","article-title":"Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes. Part B: risks of sodium-glucose co-transporter inhibitor use in type 1 diabetes and ketoacidosis risk mitigation strategies","volume":"226","author":"Ngan","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.007_bib32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2337\/dci25-0028","article-title":"Kidney disease: the forgotten legacy of type 1 diabetes","volume":"48","author":"Thomas","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.007_bib33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.kint.2019.12.021","article-title":"Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.007_bib34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13300-023-01523-0","article-title":"The effect of sodium\u2013glucose cotransporter inhibitors on renal function as adjunctive to insulin in adults with type 1 diabetes: an updated multilevel meta-analysis of randomized controlled trials","volume":"15","author":"Karakasis","year":"2024","journal-title":"Diabetes Therapy"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"Abat","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.70180","article-title":"Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: a review","volume":"28","author":"Tuttle","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.007_bib37","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"Van Raalte","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.007_bib38","article-title":"Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials","volume":"365","author":"Musso","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/dom.15047","article-title":"Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the steno T1 risk engine in adults with type 1 diabetes","volume":"25","author":"Stougaard","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.007_bib40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2215\/CJN.0000000641","article-title":"Modeling cardiorenal protection with sodium-glucose cotransporter 2 inhibition in type 1 diabetes: an analysis of DEPICT-1 and DEPICT-2","volume":"20","author":"Nardone","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib41","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1210\/clinem\/dgaf016","article-title":"Effect of sodium-glucose transporter 2 inhibitors on cardiovascular outcomes in type 1 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"110","author":"Wang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.007_bib42","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.007_bib43","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.007_bib44","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"10. cardiovascular disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.007_bib45","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2147\/DMSO.S240903","article-title":"SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations","volume":"16","author":"Maffei","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.007_bib46","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.007_bib47","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/jdi.13506","article-title":"On-label use of sodium\u2013glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes","volume":"12","author":"Horii","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc19-1481","article-title":"Use of sodium\u2013glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis","volume":"43","author":"Hampp","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.007_bib49","first-page":"572","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a","volume":"20","author":"Garg","year":"2018","journal-title":"STICH Protocol"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.007_bib50","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/1744666X.2025.2537446","article-title":"Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease","volume":"21","author":"Kugathasan","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.007_bib51","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/healthcare12070753","article-title":"Harnessing the synergy of SGLT2 inhibitors and Continuous Ketone Monitoring (CKM) in managing heart failure among patients with type 1 diabetes","volume":"12","author":"Tecce","year":"2024","journal-title":"Healthcare"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.007_bib52","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.007_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96968","article-title":"Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes","volume":"3","author":"Lovshin","year":"2018","journal-title":"JCI Insight"},{"issue":"23","key":"10.1016\/j.ecl.2026.04.007_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242317043","article-title":"Cardioprotective and antifibrotic effects of low-dose renin-angiotensin-aldosterone system inhibitors in type 1 diabetic rat model","volume":"24","author":"Balogh","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.007_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.007_bib57","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahren","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.007_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101433","article-title":"Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): a randomized double-blind placebo-controlled trial","volume":"49","author":"Thivolet","year":"2023","journal-title":"Diabetes Metab"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.007_bib59","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1111\/dom.15889","article-title":"Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Dejgaard","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.007_bib60","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.007_bib61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial\u2014a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.007_bib62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.007_bib63","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-Week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.007_bib64","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.007_bib65","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as Add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.007_bib66","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with Sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.ecl.2026.04.007_bib67","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.007_bib68","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/dom.13807","article-title":"Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial","volume":"21","author":"Kaku","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:25:28Z","timestamp":1786083928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000289"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.007","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Evidence for Cardiorenal Protection with Sodium\u2013Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}